Patrice Rioux - 31 Dec 2022 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Acting Chief Medical Officer
Signature
/s/ Kim R. Tsuchimoto, Attorney-in-fact
Issuer symbol
MNPR
Transactions as of
31 Dec 2022
Net transactions value
$0
Form type
4
Filing time
03 Jan 2023, 14:58:34 UTC
Previous filing
04 Jan 2022
Next filing
03 Jan 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Stock Options Award $0 +10,000 $0.000000 10,000 01 Jan 2023 Common Stock 10,000 $2.37 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Stock Options vesting commenced on January 1, 2023 as follows: 833 on January 31, 2023 and each subsequent month-end thereafter.